Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Litifilimab · BIIB-059

Monoclonal antibody · developed by BIOGEN

Phase 2/3 Most advanced trial
BIIB Developer
2 Registered trials

What is Litifilimab?

Litifilimab is an investigational antibody studied in Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus.

At a glance

Also known as
BIIB-059
Drug type
Monoclonal antibody
Therapy area
Dermatology, Immunology
Developer
BIOGEN (BIIB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
V27E9V3K7G

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06044337 Phase 3 Subacute Cutaneous Lupus Erythematosus Enrolling by invitation BIIB
NCT05531565 Phase 2/3 Subacute Cutaneous Lupus Erythematosus Active not recruiting BIIB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Cutaneous Lupus ErythematosusSubacute Cutaneous Lupus Erythematosus

More from BIOGEN

Dimethyl Fumarate FDA approved Diroximel Fumarate FDA approved Interferon Beta-1A FDA approved Natalizumab FDA approved Nusinersen FDA approved Omaveloxolone FDA approved Tofersen FDA approved Zuranolone FDA approved BIIB115 Phase 1 BIIB122 Phase 3 BIIB144 Phase 1 BIIB147 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BIIB page.

Follow BIIB, the company behind Litifilimab

See BIIB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIIB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.